Member Directory
Mestag is an immunotherapy company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease. Together with our collaboration partner Janssen Biotech, Inc. we are also identifying novel targets for future therapies.
Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures.
Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies.
For further information please visit our website www.mestagtherapeutics.com
Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel screening, cardiac safety profiling and drug discovery services on a fee-for-service or collaboration basis. Our aim is to provide ion channel electrophysiology expertise and high quality screening assays as part of a dedicated and flexible service tailored to customer requirements.. . Customers are able to access Metrion’s ion channel know-how and services at any point in their screening cascade. We offer a portfolio of services to add value to drug discovery programs by developing and de-risking ion channel modulators at all stages as they progress towards the clinic.
Mewburn Ellis LLP has one of the largest groups of patent attorneys specialising in biotechnology and life sciences in Europe. Our proactive approach and expertise reflect the high level work we do for a wide range of clients, from world renowned biotech companies based in the US and Europe, acting either directly or through their outside counsel, to small and medium sized companies, universities, charities, and funding bodies. We handle a substantial number of oppositions and appeals at the European patent office and have considerable expertise in drafting and prosecuting patent applications, due diligence work, infringement opinions, portfolio management and strategic patent advice.
Microbiotica is a spin out of the Wellcome Trust Sanger Institute, established to translate and commercialise ground-breaking Microbiome research from Dr Trevor Lawley's Human Microbiota Interactions Lab.
Mills Reeve is one of the UK's leading healthcare law firms and advises government, health and academic institutions on IP and related issues such as licensing, MTAs, supply of human tissue, stem cells, clinical trials and medical devices. We have extensive experience in the EU, USA, China and other countries, which allows us to help you achieve your global aspirations. . . We can help you with the concerns you may face with outsourcing agreements and collaborations, manufacturing and distribution. Our life sciences group is a full service practice and with top ranking lawyers in corporate finance and funding we can support your company from seed to listing and beyond.. . Our clients include leading biotech companies, investors, key NHS organisations, and world-class universities. Recent work has concerned new tissue legislation, patent licences and litigation, major research collaborations, clinical trials, international stem cell and blood supplies and the supply of pandemic vaccines.
Mind Over Cancer is a charity that supports the mental health and wellbeing of the whole family living with a cancer diagnosis between the ages of 0–29 years, with services that they can access at any time of life. Why? Because a cancer diagnosis doesn’t disappear when treatment stops.
When a child, teenager or young adult is diagnosed with cancer it affects the whole family. There isn’t a guidebook on how to get through it and everyone will cope with it in their own way.
Mind Over Cancer offers two services, the first being the funding of up to 10 counselling sessions, matching each client to the most appropriate counsellor for their needs. We aim to have them in their first counselling session in 2-3 weeks of receiving their referral.
The second service is an on-line support programme for people to meet others with a shared experience, groups include young people with the cancer diagnosis, siblings, parents, and friends.
A cancer diagnosis can bring different thoughts and feelings at different stages of a person’s life both during and after treatment. This is normal and for families who are living with the diagnosis it is just as important for them to look after their mental health as it is their physical health.
Talking about these thoughts and feelings when a person is ready to is very important …for many this could be years after treatment ends.
Help us to make cancer and mental health an everyday conversation.
www.mindovercancer.org.uk
Mission Street have established a market-leading and rapidly growing Science and Innovation platform.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
MISSION Therapeutics was founded in 2011. The company focuses on the biology of the DNA damage response (DDR) processes in cancer, optimising small molecule drugs to exploit synthetic lethality to selectively kill high unmet-need tumour types. Targeting deubiquitylating enzymes (DUBs) involved in regulating the DDR, MISSION has built an extensive proprietary biology and chemistry platform (Ubi-Sphere™) to support its discovery of inhibitors of DUBs. The application of DUB inhibitors extends across several therapeutic areas including neurodegeneration and infectious disease. The company is based at the Babraham Research Campus, Cambridge, UK.